177 related articles for article (PubMed ID: 15896102)
1. Cost effectiveness of imatinib compared with interferon-alpha or hydroxycarbamide for first-line treatment of chronic myeloid leukaemia.
Dalziel K; Round A; Garside R; Stein K
Pharmacoeconomics; 2005; 23(5):515-26. PubMed ID: 15896102
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness and cost-effectiveness of imatinib for first-line treatment of chronic myeloid leukaemia in chronic phase: a systematic review and economic analysis.
Dalziel K; Round A; Stein K; Garside R; Price A
Health Technol Assess; 2004 Jul; 8(28):iii, 1-120. PubMed ID: 15245690
[TBL] [Abstract][Full Text] [Related]
3. Cost-utility analysis of imatinib mesylate for the treatment of chronic myelogenous leukemia in the chronic phase.
Warren E; Ward S; Gordois A; Scuffham P
Clin Ther; 2004 Nov; 26(11):1924-33. PubMed ID: 15639704
[TBL] [Abstract][Full Text] [Related]
4. The effectiveness and cost-effectiveness of imatinib in chronic myeloid leukaemia: a systematic review.
Garside R; Round A; Dalziel K; Stein K; Royle P
Health Technol Assess; 2002; 6(33):1-162. PubMed ID: 12633529
[No Abstract] [Full Text] [Related]
5. Dasatinib, high-dose imatinib and nilotinib for the treatment of imatinib-resistant chronic myeloid leukaemia: a systematic review and economic evaluation.
Loveman E; Cooper K; Bryant J; Colquitt JL; Frampton GK; Clegg A
Health Technol Assess; 2012; 16(23):iii-xiii, 1-137. PubMed ID: 22564553
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of imatinib versus interferon-alpha plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia.
Reed SD; Anstrom KJ; Ludmer JA; Glendenning GA; Schulman KA
Cancer; 2004 Dec; 101(11):2574-83. PubMed ID: 15493042
[TBL] [Abstract][Full Text] [Related]
7. [Drug treatment of chronic myeloid leukemia: a cost effectiveness analysis of first- and second-line treatment ].
Groot MT; Ossenkoppele GJ; Kramer MH; van den Boom G; Huijgens PC; Uyl-de Groot CA
Ned Tijdschr Geneeskd; 2003 Jul; 147(30):1460-5. PubMed ID: 12908349
[TBL] [Abstract][Full Text] [Related]
8. Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia: systematic reviews and economic analyses.
Pavey T; Hoyle M; Ciani O; Crathorne L; Jones-Hughes T; Cooper C; Osipenko L; Venkatachalam M; Rudin C; Ukoumunne O; Garside R; Anderson R
Health Technol Assess; 2012; 16(42):iii-iv, 1-277. PubMed ID: 23134589
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness study comparing imatinib with interferon-alpha for patients with newly diagnosed chronic-phase (CP) chronic myeloid leukemia (CML) from the Chinese public health-care system perspective (CPHSP).
Chen Z; Wang C; Xu X; Feng W
Value Health; 2009; 12 Suppl 3():S85-8. PubMed ID: 20586990
[TBL] [Abstract][Full Text] [Related]
10. Position paper on imatinib mesylate in chronic myeloid leukaemia.
O'Brien SG; Rule SA
Br J Haematol; 2002 Oct; 119(1):268-72. PubMed ID: 12358935
[No Abstract] [Full Text] [Related]
11. Is imatinib a cost-effective treatment for newly diagnosed chronic myeloid leukemia patients?
Goldman J
Nat Clin Pract Oncol; 2005 Mar; 2(3):126-7. PubMed ID: 16264901
[No Abstract] [Full Text] [Related]
12. Cost-effectiveness of dasatinib and nilotinib for imatinib-resistant or -intolerant chronic phase chronic myeloid leukemia.
Hoyle M; Rogers G; Moxham T; Liu Z; Stein K
Value Health; 2011 Dec; 14(8):1057-67. PubMed ID: 22152175
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of 3-years of adjuvant imatinib in gastrointestinal stromal tumors (GIST) in the United States.
Sanon M; Taylor DC; Parthan A; Coombs J; Paolantonio M; Sasane M
J Med Econ; 2013; 16(1):150-9. PubMed ID: 22762291
[TBL] [Abstract][Full Text] [Related]
14. Cost utility of allogeneic stem cell transplantation with matched unrelated donor versus treatment with imatinib for adult patients with newly diagnosed chronic myeloid leukaemia.
Breitscheidel L
J Med Econ; 2008; 11(4):571-84. PubMed ID: 19450068
[TBL] [Abstract][Full Text] [Related]
15. Imatinib for chronic myeloid leukaemia: a NICE mess.
Rajaratnam G; Edwards J
Lancet; 2001 Dec; 358(9296):1902. PubMed ID: 11741655
[No Abstract] [Full Text] [Related]
16. Ponatinib for Treating Acute Lymphoblastic Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Stevenson M; Pandor A; Hamilton J; Stevens J; Rowntree C; Martyn-St James M; Rawdin A; Wong R
Pharmacoeconomics; 2018 Jul; 36(7):759-768. PubMed ID: 29502175
[TBL] [Abstract][Full Text] [Related]
17. Societal implications of medical insurance coverage for imatinib as first-line treatment of chronic myeloid leukemia in China: a cost-effectiveness analysis.
Sheng G; Chen S; Dong C; Zhang R; Miao M; Wu D; Tan SC; Liu C; Xiong T
J Med Econ; 2017 Apr; 20(4):371-381. PubMed ID: 27936995
[TBL] [Abstract][Full Text] [Related]
18. Cost-efficacy of imatinib versus allogeneic bone marrow transplantation with a matched unrelated donor in the treatment of chronic myelogenous leukemia: a decision-analytic approach.
Skrepnek GH; Ballard EE
Pharmacotherapy; 2005 Mar; 25(3):325-34. PubMed ID: 15843279
[TBL] [Abstract][Full Text] [Related]
19. Imatinib for the treatment of patients with unresectable and/or metastatic gastrointestinal stromal tumours: systematic review and economic evaluation.
Wilson J; Connock M; Song F; Yao G; Fry-Smith A; Raftery J; Peake D
Health Technol Assess; 2005 Jul; 9(25):1-142. PubMed ID: 15985189
[TBL] [Abstract][Full Text] [Related]
20. Treatment value of second-generation BCR-ABL1 tyrosine kinase inhibitors compared with imatinib to achieve treatment-free remission in patients with chronic myeloid leukaemia: a modelling study.
Shih YT; Cortes JE; Kantarjian HM
Lancet Haematol; 2019 Aug; 6(8):e398-e408. PubMed ID: 31208943
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
